In adults with standard-risk acute lymphoblastic leukemia, the greatest benefit is achieved from a matched sibling allogeneic transplantation in first complete remission, and an autologous transplantation is less effective than conventional consolidation/maintenance chemotherapy in all patients: fin
暂无分享,去创建一个
M. Tallman | S. Richards | L. Foroni | R. Chopra | H. Lazarus | E. Paietta | J. Rowe | A. Fielding | A. Goldstone | A. Burnett | M. Litzow | S. Luger | G. Buck | D. Marks | P. Wiernik | A. McMillan | I. Franklin | J. Durrant | N. Ciobanu
[1] T. Szczepański. Why and how to quantify minimal residual disease in acute lymphoblastic leukemia? , 2007, Leukemia.
[2] A. Periclou,et al. Pharmacodynamics and safety of intravenous pegaspargase during remission induction in adults aged 55 years or younger with newly diagnosed acute lymphoblastic leukemia. , 2007, Blood.
[3] M. Loh,et al. Favorable outcome for adolescents with acute lymphoblastic leukemia treated on Dana-Farber Cancer Institute Acute Lymphoblastic Leukemia Consortium Protocols. , 2007, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[4] S. Forman,et al. 369: Reduced-intensity stem cell transplantation for high-risk acute lymphoblastic leukemia , 2007 .
[5] M. Kneba,et al. Molecular relapse in adult standard-risk ALL patients detected by prospective MRD monitoring during and after maintenance treatment: data from the GMALL 06/99 and 07/03 trials. , 2007, Blood.
[6] A. Cherry,et al. Karyotype is an independent prognostic factor in adult acute lymphoblastic leukemia (ALL): analysis of cytogenetic data from patients treated on the Medical Research Council (MRC) UKALLXII/Eastern Cooperative Oncology Group (ECOG) 2993 trial. , 2005, Blood.
[7] A. Mato,et al. Autologous stem cell transplant in ALL: who should we be transplanting in first remission? , 2006, Bone Marrow Transplantation.
[8] E. Thiel,et al. Clinical significance of minimal residual disease quantification in adult patients with standard-risk acute lymphoblastic leukemia. , 2006, Blood.
[9] C. Pui,et al. Treatment of acute lymphoblastic leukemia. , 2006, The New England journal of medicine.
[10] D. Hoelzer,et al. Treatment of adult acute lymphoblastic leukemia. , 1999, Hematology. American Society of Hematology. Education Program.
[11] 渡辺 克哉,et al. 難治性造血器腫瘍に対するreduced-intensity stem cell transplantation (第39回 日本無菌生物ノートバイオロジー学会総会) , 2006 .
[12] N. Kröger,et al. Comparable results in patients with acute lymphoblastic leukemia after related and unrelated stem cell transplantation , 2006, Bone Marrow Transplantation.
[13] M. Tallman,et al. Induction therapy for adults with acute lymphoblastic leukemia: results of more than 1500 patients from the international ALL trial: MRC UKALL XII/ECOG E2993. , 2005, Blood.
[14] R. Foà,et al. A comprehensive genetic classification of adult acute lymphoblastic leukemia (ALL): analysis of the GIMEMA 0496 protocol. , 2005, Blood.
[15] H. Kantarjian,et al. Long‐term follow‐up results of hyperfractionated cyclophosphamide, vincristine, doxorubicin, and dexamethasone (Hyper‐CVAD), a dose‐intensive regimen, in adult acute lymphocytic leukemia , 2004, Cancer.
[16] P. Sonneveld,et al. Significant difference in outcome for adolescents with acute lymphoblastic leukemia treated on pediatric vs adult protocols in the Netherlands , 2004, Leukemia.
[17] M. Béné,et al. Better outcome of adult acute lymphoblastic leukemia after early genoidentical allogeneic bone marrow transplantation (BMT) than after late high-dose therapy and autologous BMT: a GOELAMS trial. , 2004, Blood.
[18] H. Dombret,et al. Outcome of treatment in adults with acute lymphoblastic leukemia: analysis of the LALA-94 trial. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[19] V. Diehl,et al. Outcome of allogeneic hematopoietic stem-cell transplantation in adult patients with acute lymphoblastic leukemia: no difference in related compared with unrelated transplant in first complete remission. , 2004, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[20] J. Bourhis,et al. Allogeneic stem cell transplantation in acute lymphoblastic leukemia and non-Hodgkin’s lymphoma for patients ≤£ 50 years old in first complete remission: results of the EORTC ALL-3 trial , 2004 .
[21] D. Hoelzer,et al. Treatment with monoclonal antibodies in acute lymphoblastic leukemia: current knowledge and future prospects , 2004, Annals of Hematology.
[22] M. Tallman,et al. The outcome of 267 Philadelphia positive adults in the international UKALL12/ECOG E 2993 study. Final analysis and the role of allogeneic transplant in those under 50 years. , 2003 .
[23] C. Schiffer. Differences in outcome in adolescents with acute lymphoblastic leukemia: a consequence of better regimens? Better doctors? Both? , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[24] T. Kyo,et al. Induction therapy by frequent administration of doxorubicin with four other drugs, followed by intensive consolidation and maintenance therapy for adult acute lymphoblastic leukemia: the JALSG-ALL93 study , 2002, Leukemia.
[25] D. Wall,et al. Unrelated marrow transplantation for children with acute lymphoblastic leukemia in second remission. , 2002, Blood.
[26] M. Baccarani,et al. Treatment of adult acute lymphoblastic leukemia (ALL): long-term follow-up of the GIMEMA ALL 0288 randomized study. , 2002, Blood.
[27] B. Löwenberg,et al. Unrelated marrow transplantation for adult patients with poor-risk acute lymphoblastic leukemia: strong graft-versus-leukemia effect and risk factors determining outcome. , 2001, Blood.
[28] R. Gelber,et al. Improved outcome for children with acute lymphoblastic leukemia: results of Dana-Farber Consortium Protocol 91-01. , 2001, Blood.
[29] C. Sebban,et al. Adult acute lymphocytic leukemia study testing chemotherapy and autologous and allogeneic transplantation. A follow-up report of the French protocol LALA 87. , 2000, Hematology/oncology clinics of North America.
[30] D. Hoelzer,et al. New approaches to acute lymphoblastic leukemia in adults: where do we go? , 2000, Seminars in oncology.
[31] W. Hiddemann,et al. Improved outcome in childhood acute lymphoblastic leukemia despite reduced use of anthracyclines and cranial radiotherapy: results of trial ALL-BFM 90. German-Austrian-Swiss ALL-BFM Study Group. , 2000, Blood.
[32] C. Bloomfield,et al. Prospective karyotype analysis in adult acute lymphoblastic leukemia: the cancer and leukemia Group B experience. , 1999, Blood.
[33] Edward J. Lee,et al. A randomized controlled trial of filgrastim during remission induction and consolidation chemotherapy for adults with acute lymphoblastic leukemia: CALGB study 9111. , 1998, Blood.
[34] Z. Estrov,et al. Clinical significance of cytogenetic abnormalities in adult acute lymphoblastic leukemia. , 1998, Blood.
[35] H. Prentice,et al. The impact of age on outcome in lymphoblastic leukaemia; MRC UKALL X and XA compared: a report from the MRC Paediatric and Adult Working Parties , 1998, Leukemia.
[36] R. Larson,et al. Treatment of adult acute lymphoblastic leukemia. , 1997, Seminars in oncology.
[38] R. Larson,et al. A five-drug remission induction regimen with intensive consolidation for adults with acute lymphoblastic leukemia: cancer and leukemia group B study 8811. , 1995, Blood.
[39] C. Gisselbrecht,et al. Adult acute lymphoblastic leukemia: a multicentric randomized trial testing bone marrow transplantation as postremission therapy. The French Group on Therapy for Adult Acute Lymphoblastic Leukemia. , 1993, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[40] A. Ganser,et al. Prognostic factors in a multicenter study for treatment of acute lymphoblastic leukemia in adults , 1988 .
[41] R. Storb,et al. Antileukemic effect of graft-versus-host disease in human recipients of allogeneic-marrow grafts. , 1979, The New England journal of medicine.
[42] J. Burchenal,et al. Treatment of acute lymphoblastic leukemia. , 1972, Annual review of medicine.